Core Viewpoint - Pfizer's Q2 earnings exceeded expectations, driven by strong demand for heart disease drug Vyndaqel and anticoagulant Eliquis, leading to a stock price increase of over 4% [1] Financial Performance - Q2 revenue reached $14.7 billion, surpassing the expected $13.47 billion [1] - Earnings per share (EPS) were $0.78, exceeding the forecast of $0.57 [1] Future Guidance - Pfizer raised its adjusted EPS forecast for 2025 to a range of $2.90 to $3.10, up from the previous estimate of $2.80 to $3.00 [1] - The midpoint of the adjusted EPS outlook was increased by $0.10, above the market consensus of $3.01 [1] - The full-year revenue guidance remains unchanged at $61 billion to $64 billion [1]

Core Viewpoint - Pfizer's strong Q2 performance driven by robust demand for heart disease drug Vyndaqel and anticoagulant Eliquis, leading to revenue and profit exceeding expectations [1] Financial Performance - Q2 revenue reached $14.7 billion, surpassing the expected $13.47 billion [1] - Earnings per share (EPS) were $0.78, exceeding the forecast of $0.57 [1] Future Guidance - Pfizer projects adjusted EPS for 2025 to be between $2.90 and $3.10, up from the previous estimate of $2.80 to $3.00 [1] - The midpoint of the adjusted EPS outlook is raised by $0.10, above the market consensus of $3.01 [1] - Full-year revenue guidance remains unchanged at $61 billion to $64 billion [1]